Estimation of Premature Deaths From Lack of Access to Anti-HER2 Therapy for Advanced Breast Cancer in the Brazilian Public Health System
Márcio Debiasi, Tomás Reinert, Rafael Kaliks, Gilberto Amorim, Maira Caleffi, Carlos Sampaio, Gustavo dos Santos Fernandes and Carlos H. BarriosJournal of Global Oncology 3, no. 3 (June 2017) 201-207. Full link: https://ascopubs.org/doi/full/10.1200/JGO.2016.005678
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)
Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). In this context, alternatives to the lapatinib (L) and capecitabine (C) regimen, evaluating L combined with other cytotoxic drugs, are warranted.
Incidence and mortality rates of breast and gynecologic cancers and human development index in the pan-American region
Jeovany Martínez-Mesa, Gustavo Werutsky, Carlos Alberto Sampaio-Filho, Aknar Calabrich, Carlos H. Barrios J Clin Oncol 31, 2013 (suppl; abstr e12510) Full link: https://meetinglibrary.asco.org/record/96361/abstract
A phase II randomized study of lapatinib in combination with capecitabine, vinorelbine or gemcitabine as first or second line-therapy in patients with HER2 positive metastatic breast cancer progressing after taxane
(LACOG 0801).Gomez H, Neciosup S, Tosello C, Mano M, Bines J, Ismael G, Santi PX, Pinczowsky H, Neron Y, Fanelli M, Fein L, Sampaio C, Lerzo G, Capo A, Zarba JJ, Blajman C, Varela MS, Martínez-Mesa J, Werutsky G, Barrios CH.San Antonio Breast Cancer Symposium 2013; Abstract P4-12-26 Full link: https://cancerres.aacrjournals.org/content/73/24_Supplement/P4-12-26
Breast cancer in Brazil: present status and future goals.
Lee BL, Liedke PE, Barrios CH, Simon SD, Finkelstein DM, Goss PE.
A randomized, open-label, phase II study of lapatinib / capecitabine, lapatinib / vinorelbine, or lapatinib / gemcitabine in patients with ErbB2-amplified metastatic breast cancer progressing after taxane treatment: Results of an interim analysis
(GLICO-0801 / EGF111792).Henry Leonidas Gomez, Silvia P. Neciosup, Celia Tosello, Patricia Xavier, Yeni Neron do Nascimento, Marcelo Fanelli, Gustavo Ismael, Jose Bines, Carlos Sampaio, Guillermo Luis Lerzo, Adolfo Miguel Capo, Max S. Mano, Luis Fein, Gustavo Werutsky, Carlos H. BarriosJ Clin Oncol 30, 2012 (suppl; abstr e11087) Full link: https://meetinglibrary.asco.org/record/73652/abstract